Alongside our long-standing obsession with artisanally crafted cuisine rests a similar fixation on elevated cocktails crafted ...

I saw several young women, spring-breakers maybe, at Harris Teeter not long ago – wearing bell-bottom jeans. I mentioned this ...

Presenting CPE programs is satisfying, helps sharpen your knowledge, is great for networking with colleagues, and sometimes ...

The new, proprietary target discovery platform integrates RWD, human biological modeling, and CRISPR screens to accelerate novel target identification CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ ...

In the last three months, 9 analysts have published ratings on Tempus AI TEM, offering a diverse range of perspectives from bullish to bearish. The table below provides a snapshot of their recent ...

The companies will use the AI-based platform to accelerate cancer drug discovery. Credit: sanjeri via Getty Images. AstraZeneca, Tempus and Pathos AI have signed a multi-year agreement to develop a ...

The platform enables an understanding of the interactions between T cell receptors and their corresponding antigenic epitopes. Credit: THICHA SATAPITANON / Shutterstock. Repertoire Immune Medicines ...

Investing.com -- Tempus AI Inc (NASDAQ:TEM) shares closed up 14.5% following the announcement of expanded strategic partnerships with AstraZeneca (NASDAQ:AZN) and Pathos AI, Inc. The ...

Tempus AI shares were 14% higher, at $49.35, after the company said it has entered into multi-year strategic collaborations with AstraZeneca and Pathos AI. The technology company said the ...